Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

Commenting on a recently published article on sicca syndrome linked to immune checkpoint inhibitor therapy, this letter to the editor shares another viewpoint on the management of this immune‐related adverse event.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The oncologist (Dayton, Ohio) Ohio), 2020-02, Vol.25 (2), p.e391-e395
Hauptverfasser: Ortiz Brugués, Ariadna, Sibaud, Vincent, Herbault‐Barrés, Beatrice, Betrian, Sarah, Korakis, Iphigenie, De Bataille, Caroline, Gomez‐Roca, Carlos, Epstein, Joel, Vigarios, Emmanuelle
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Commenting on a recently published article on sicca syndrome linked to immune checkpoint inhibitor therapy, this letter to the editor shares another viewpoint on the management of this immune‐related adverse event.
ISSN:1083-7159
1549-490X
DOI:10.1634/theoncologist.2019-0467